Within the PROVEO collaborative partnership, Cerbios will perform process development and manufacture of the cytotoxic drug-linker payload, and the subsequent conjugation to the monoclonal antibody to produce the ADC drug substance.
The above mentioned services in combination with monoclonal antibody production by CMC Biologics and sterile filling of the ADC drug product by Oncotec, along with analytical and quality services throughout the PROVEOTM supply chain, as well as secondary packaging through to ready-to-sell final drug product by IDT Biologika will be available to clients beginning in 2017 and will further enhance PROVEOTM `s full ADC service offering.
Development and manufacturing of
- Monoclonal antibody (alliance partner or small scale in-house)
- Payloads (Linker + Cytotoxic Warhead)
- Formulation development and Fill & Finish (alliance partner)
- Labeling and packaging (alliance partner)
Cerbios has internal capabilities to manufacture single components of the ADC, along with the conjugation process, as well as the flexibility to run the conjugation between payload and mAbs coming from third party manufacturers.